Estring

Atrophic Vaginitis, Low Testosterone, Hypogonadism + 27 more
Treatment
5 FDA approvals
20 Active Studies for Estring

What is Estring

EstradiolThe Generic name of this drug
Treatment SummaryEstradiol is a hormone that is naturally found in women and is used to treat conditions caused by low estrogen levels, such as hot flashes and vaginal dryness. It comes in several forms, including tablets, injections, vaginal rings, patches, sprays, gels, and creams. Ethinyl estradiol is a synthetic form of estradiol that is commonly used in oral contraceptives. It is more effective when taken orally than estradiol because it has a higher bioavailability and is more resistant to being broken down in the body.
Estradermis the brand name
image of different drug pills on a surface
Estring Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Estraderm
Estradiol
1986
373

Approved as Treatment by the FDA

Estradiol, also known as Estraderm, is approved by the FDA for 5 uses like Breast Cancer and Hormonal Contraception .
Breast Cancer
Hormonal Contraception
Used to treat Hormonal Contraception therapy in combination with Levonorgestrel
Birth Control
Used to treat Contraception in combination with Levonorgestrel
Palliative Treatment
Breast Cancer

Effectiveness

How Estring Affects PatientsEstradiol is a hormone that helps to reduce hot flashes, vaginal dryness, and pain during sex. It can also increase bone density and have positive effects on the body's cholesterol levels. Estradiol can also increase certain proteins in the liver, such as sex hormone binding globulin and thyroid-binding globulin, and suppress the formation of follicle-stimulating hormone. However, it can also increase the risk of cardiovascular disease, deep vein thrombosis, and stroke, so it should be avoided in people at high risk for these conditions. Additionally, estradiol can cause a hyper-coagul
How Estring works in the bodyEstrogen is found in many parts of the body and is produced mainly by the ovarian follicles in women who are still going through their reproductive period. After menopause, most estrogen is made by transforming androstenedione (from the adrenal cortex) to estrone. Estrogen works by binding to receptors in the body, including ERα and ERβ, which then enter the nucleus of the target cell and activate certain genes. This process causes the body to produce proteins that express the effects of estradiol. Estrogen has a range of effects, including reducing hot flashes, chills, mood swings, and sleep problems in

When to interrupt dosage

The encouraged measure of Estring is subject to the determined condition, for example, Premature Menopause, Pharmaceutical Preparations and Postmenopause. The amount of dosage is contingent on the technique of administration enumerated in the table beneath.
Condition
Dosage
Administration
Osteoporosis
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Hormone Replacement Therapy
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Postmenopause
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Palliative Treatment
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Atrophic
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Vasomotor System
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Hormonal Contraception
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Balanitis Xerotica Obliterans
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Prostate Cancer
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Breast
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Therapeutic procedure
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Osteoporosis, Postmenopausal
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Pharmaceutical Preparations
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Premature Menopause
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
female castration
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
estradiol
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Hot flashes
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Hypogonadism
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
hypoestrogenism
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Breast Cancer
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Warnings

Estring has eighteen contraindications. It should not be utilized in combination with the ailments presented in the following table.Estring Contraindications
Condition
Risk Level
Notes
Breast
Do Not Combine
Angioedema
Do Not Combine
Venous Thrombosis
Do Not Combine
undiagnosed abnormal genital bleeding
Do Not Combine
estrogen-dependent neoplasia
Do Not Combine
Liver Dysfunction
Do Not Combine
Breast
Do Not Combine
suspected pregnancy
Do Not Combine
Breast Cancer
Do Not Combine
Pulmonary Embolism
Do Not Combine
Angioedema
Do Not Combine
Deep Vein Thrombosis
Do Not Combine
Thromboembolism
Do Not Combine
Neoplasms, Hormone-Dependent
Do Not Combine
Pulmonary Embolism
Do Not Combine
Thromboembolism
Do Not Combine
Thrombophilia
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Estradiol may interact with Pulse Frequency
There are 20 known major drug interactions with Estring.
Common Estring Drug Interactions
Drug Name
Risk Level
Description
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Estradiol.
Anagrelide
Major
The metabolism of Anagrelide can be decreased when combined with Estradiol.
Anastrozole
Major
The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estradiol.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Estradiol.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Estradiol.
Estring Toxicity & Overdose RiskThe amount of estradiol that is considered safe for rats to consume orally over a 90-day period is 0.003mg/kg/day. The highest dose of estradiol that has been found to be toxic to humans is 21mg/kg/21 days. Symptoms of estradiol overdose may include nausea, vomiting, abdominal pain, breast tenderness, blood clots, or vaginal bleeding. If an overdose occurs, it is recommended to cease using estradiol and provide supportive care.

Estring Novel Uses: Which Conditions Have a Clinical Trial Featuring Estring?

Currently, 867 clinical trials are assessing the potential of Estring to address Osteoporosis, Absent Menses for 6 Months or More and Urogenital Atrophy.
Condition
Clinical Trials
Trial Phases
Hysterectomy
3 Actively Recruiting
Phase 3, Not Applicable
Breast Cancer
21 Actively Recruiting
Phase 2, Phase 1, Not Applicable
estradiol
0 Actively Recruiting
Birth Control
22 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2
Postmenopause
5 Actively Recruiting
Phase 2, Not Applicable
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
Osteoporosis, Postmenopausal
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
moderate to severe symptoms
0 Actively Recruiting
Balanitis Xerotica Obliterans
0 Actively Recruiting
Amenorrhea
1 Actively Recruiting
Phase 2
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2
Prostate Cancer
69 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 1, Early Phase 1
Breast
0 Actively Recruiting
Urogenital atrophy
0 Actively Recruiting
Low Testosterone
6 Actively Recruiting
Phase 4, Phase 2, Phase 1
Vasomotor System
0 Actively Recruiting
Atrophic Vaginitis
1 Actively Recruiting
Not Applicable
Hot flashes
19 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3
Hormone Replacement Therapy
0 Actively Recruiting

Estring Reviews: What are patients saying about Estring?

5Patient Review
5/5/2020
Estring for Vaginal Inflammation due to Loss of Hormone Stimulation
I've been using this for three months now and the only possible side effect is that my vision has gotten worse. I'm 59, so it might just be age. However, I can tell a difference in my vaginal tone and lubrication.
5Patient Review
12/15/2020
Estring for Postmenopausal Urethral Atrophy
I bled for two days after sex, even though I had been using the vaginal cream for a year. But then I tried Estring and felt normal again within a month. The only downside is that now I can't afford it because I'm on Medicare. It's really sad that those who need it the most can't use the coupon.
5Patient Review
5/20/2021
Estring for Postmenopausal Urethral Atrophy
Estring is great! Easy to use and comfortable. No mess! BUT don't waste your time until you know if your insurance covers it!
5Patient Review
2/16/2022
Estring for Vaginal Inflammation due to Loss of Hormone Stimulation
I was so pleased with E String, and it worked perfectly for me for over two years. But then my consultant said I needed to take a break from it, and my GP couldn't tell me when or if I could use it again. Now my symptoms have returned and I'm using Vagirux instead, but I really want to go back on E String.
5Patient Review
7/28/2022
Estring for Postmenopausal Urethral Atrophy
So far, I've been really pleased. It's easy to insert and there's no discomfort. I'm only a week in, but fingers crossed it will help with the pain and dryness I experience during sex.
4.7Patient Review
5/24/2021
Estring for Postmenopausal Urethral Atrophy
I love this product, but I'm infuriated by how much more expensive it is for women than men's medication. It's not fair, and it puts a huge financial burden on already disadvantaged people.
4.3Patient Review
4/6/2021
Estring for Postmenopausal Urethral Atrophy
The ring was a bit tough to remove, but I'm glad I stuck it out. It would have been helpful to know what the ideal feeling should be when removing the ring.
3.7Patient Review
6/23/2020
Estring for Postmenopausal Urethral Atrophy
I love the Estring BUT why is its so hard to remove. I cannot do it by myself. Manufacturer should provide a device to remove it....I had a kind of "hook" to use when I had a diaphragm years ago.
3.3Patient Review
11/15/2020
Estring for Postmenopausal Urethral Atrophy
The estring helped with my vaginal dryness and atrophy, as well as the pain I experienced during sex. However, there was a lot of discharge while using it. After eight months, I developed a bacterial infection which my doctor said was likely due to the estring. So, after finishing antibiotics, I'll be trying an estrogen cream instead.
3Patient Review
9/13/2021
Estring for Postmenopausal Urethral Atrophy
I've used this for the past three years, but I can't seem to remove it on my own. My husband has to help me take it out. Additionally, I think it's caused me to gain weight around my middle.
1Patient Review
2/26/2022
Estring for Postmenopausal Urethral Atrophy
I wasn't able to use this product because the ring is too large. Additionally, the contour makes it very difficult and uncomfortable to insert.
1Patient Review
8/15/2022
Estring for Vaginal Inflammation due to Loss of Hormone Stimulation
The ring is very hard and big! I had a hard time getting it in and even worse trying to get it out. I used it for two weeks but got a bacterial infection so I stopped using it. The side effects weren't worth it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about estring

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the estring cause weight gain?

"Studies show that there is no link between estrogen and weight gain. The estrogen ring is not a factor in weight gain. Common factors that contribute to weight gain are age and lifestyle."

Answered by AI

What is estring used for?

"Estring is a soft, flexible ring used after menopause that continuously releases an estrogen over 3 months to treat menopausal changes in and around the vagina. It is important to keep in mind that estrogen therapies such as Estring should be used only as long as they are needed."

Answered by AI

Is estring considered HRT?

"There are two main types of HRT vaginal rings: Estring (estradiol) and Femring (estradiol acetate)."

Answered by AI

How long do you leave estring in?

"After 90 days of continued use, you and your doctor should talk about whether you still need treatment with Estring."

Answered by AI

Clinical Trials for Estring

Image of Altasciences in Mount Royal, Canada.

Elinzanetant for Hot Flashes

18 - 65
Female
Mount Royal, Canada
The aim of this study is to examine the relative bioavailability of elinzanetant when administered in new oral formulations (treatment B and C) after both single and multiple oral doses, compared to its administration in soft gel capsule form (treatment A). Study details include: An ambulatory screening visit within 4 weeks prior to first treatment. Participants will be admitted to the ward on Day -1 of each period. On Day 1, either treatment B or treatment C will be administered fasted in the evening, followed by blood sampling for a 24-hour pharmacokinetic (PK) profile. On Day 2, the multiple dosing starts 3 hours after a standardized dinner in the evening. After the last dosing on Day 7, a complete PK profile for 24 hours will be collected. If there are no medical objections, participants will be discharged from the study ward on Day 9 in the morning for a washout-out period of at least 10 days (240 hours after last dosing, after period 1 and 2) or, in period 3, after the follow-up examination. The total duration of the study will be approximately 10 to 12 weeks for each participant.
Phase 1
Recruiting
AltasciencesBayer
Image of Washington University School of Medicine in St Louis, United States.

Radium-223 for Prostate Cancer

18+
Male
St Louis, MO
Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased cells while sparing adjacent normal tissues. \[223Ra\]RaCl2 (Xofigo) is the first FDA-approved alpha-particle emitting radiopharmaceutical therapy (αRPT), providing a survival benefit for men with bone metastatic castration-resistant prostate cancer. Systemically administered radiotherapies distribute throughout the patient, accumulating to unknown levels at sites of disease and in radiosensitive vital organs. The whole-body distribution means that absorbed doses in the patient extend far beyond a pre-defined treatment field. There is a lack of information about αRPT distribution and localization, and this confounds treatment monitoring, complicates dose and schedule personalization, and impedes drug development. Single-photon emission computed tomography (SPECT) imaging offers a mechanism to quantify uptake; however, αRPT administered activities are significantly lower than those used with diagnostic procedures, which presents a challenge for quantitation with conventional methods. Preliminary research shows that low-count quantitative SPECT (LC-QSPECT) imaging demonstrates reliable quantitation of regional uptake for αRPTs. The purpose of this study is to demonstrate the feasibility, tolerability and performance of LC-QSPECT imaging.
Waitlist Available
Has No Placebo
Washington University School of MedicineAbhinav K Jha, Ph.D.
Image of City of Hope Medical Center in Duarte, United States.

Oral Cryotherapy for Prostate Cancer

18+
Male
Duarte, CA
This clinical trial studies whether cooling the mouth with popsicles (oral cryotherapy) decreases taste changes in prostate cancer patients receiving taxane chemotherapy. Patients receiving chemotherapy can experience a variety of side effects. Changes in the taste of food is a frequent complaint of patients receiving chemotherapy and is underreported as patients may think that it is unavoidable and not manageable. Taxane-based chemotherapy is thought to be associated with the most taste changes of any chemotherapy. Taste buds contain a specific type of cell, called gustatory cells, that are located on the surface of the tongue, the soft palate (back, muscular part of the roof of the mouth), and the upper part of the esophagus. These cells consist of five basic tastes: salty, sweet, sour, bitter, and umami (or savory). Oral cryotherapy involves cooling the mouth with ice chips, popsicles, or other cold drinks for several minutes before, during, and after chemotherapy causing the tiny blood vessels in the protective linings inside the mouth to narrow. It is thought that this narrowing will reduce blood flow to the cooled areas, thereby decreasing the amount of chemotherapy that is delivered to the fragile protective linings inside the mouth that causes the taste changes. This may be an effective way to decrease taste changes in prostate cancer patients receiving taxane chemotherapy.
Recruiting
Has No Placebo
City of Hope Medical CenterJeannine M Brant
Have you considered Estring clinical trials? We made a collection of clinical trials featuring Estring, we think they might fit your search criteria.Go to Trials
Image of City of Hope Medical Center in Duarte, United States.

Metabolic Interventions for Prostate Cancer

30 - 79
Male
Duarte, CA
This phase II trial compares the effect of time-restricted eating (TRE) and glucagon-like peptide-1 (GLP1) receptor agonists (RA), semaglutide and tirzepatide, to an American Heart Association (AHA) heart healthy diet (HHD) intervention on heart and blood vessel health (cardiovascular system) and how the body processes food for energy (metabolic system) in prostate cancer patients undergoing androgen deprivation therapy (ADT). Prostate cancer patients who are receiving hormonal therapy (ADT) are at an increased risk of cardiovascular disease. This is thought to be due to treatment-related metabolic changes which may result in increased weight, body fat, insulin resistance and an increased risk of heart attack, stroke or other heart and blood vessel problems. TRE (also known as intermittent fasting) is an eating plan that alternates between fasting and non-fasting periods. This approach limits calorie intake to a specific window of time each day. GLP1-RAs, semaglutide and tirzepatide are in a class of medications called incretin mimetics. They work by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. They also slow the movement of food through the stomach and may decrease appetite and cause weight loss. The AHA HHD guidelines may be an effective method to help people learn about following a heart healthy eating plan. This may lower their risk of cardiovascular disease. Metabolic interventions, TRE and GLP1-RA, may be more effective than an AHA HHD intervention alone in improving cardiovascular and metabolic health in prostate cancer patients undergoing ADT.
Phase 2
Recruiting
City of Hope Medical CenterRose Li
Image of UCLA / Jonsson Comprehensive Cancer Center in Los Angeles, United States.

Flotufolastat F 18 PET/CT for Prostate Cancer

18 - 90
Male
Los Angeles, CA
This phase II trial evaluates how well flotufolastat F 18 positron emission tomography (PET)/computed tomography (CT) imaging works to detect cancer that remains (residual) or that has come back (recurrent) after the completion of focal therapy for prostate cancer. Flotufolastat F 18 is a radioactive tracer that binds to prostate specific membrane antigen (PSMA), a protein over-expressed on prostate tumor cells. This allows for visualization of PSMA-expressing cells upon imaging. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of, in the case of this research, flotufolastat F 18. Because prostate cancer takes up flotufolastat F 18, it can be seen with PET. CT utilizes x-rays that track the body from the outside. CT images provide an exact outline of the organs and potential inflammatory tissue where it occurs in the body. The PET/CT scanner combines the PET and the CT scanners into a single device. This device combines the anatomic (body structure) information provided by the CT scan with the metabolic information obtained from the PET scan. Metabolic information means how much of the injected tracer is taken up by inflammatory tissue. Flotufolastat F 18 PET/CT imaging may be an effective and less invasive way to detect residual or recurrent disease in prostate cancer patients, compared to other methods.
Phase 2
Recruiting
UCLA / Jonsson Comprehensive Cancer CenterWayne BrisbaneBlue Earth Diagnostics
Image of UCLA / Jonsson Comprehensive Cancer Center in Los Angeles, United States.

PSMA Imaging for Prostate Cancer

18 - 90
Male
Los Angeles, CA
This early phase I trial evaluates whether a new imaging technique using flotufolastat F 18 (a type of prostate specific membrane antigen \[PSMA\] imaging agent) with positron emission tomography (PET)/computed tomography (CT) can be used to guide targeted prostate biopsies in men with prostate cancer. Flotufolastat F 18 is a radioactive imaging agent that binds to prostate tumor cells that express PSMA. This allows for visualization of PSMA-expressing tumor cells on imaging scans such as PET/CT. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, flotufolastat F 18. Because prostate cancer takes up flotufolastat F 18, it can be seen with PET. CT utilizes X-rays that track the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in the body. The PET/CT scanner combines the PET and the CT scanners into a single device. A targeted prostate biopsy refers to using advanced imaging for guidance when taking samples (biopsies) of the prostate. This method can fuse (combine) PET/CT images with real-time ultrasound during a prostate biopsy. PSMA PET/CT scans have the potential for guiding prostate biopsies. Using image fusion technology, they can increase detection of prostate cancer by providing anatomical information and guidance during a prostate biopsy. Improved detection of prostate cancer using PSMA PET/CT guidance may better inform men and their clinicians about prostate cancer risk and management. This study attempts to determine how often prostate cancer is found when using PSMA PET/CT scan images during a biopsy versus the conventional magnetic resonance imaging-guidance.
Phase < 1
Recruiting
UCLA / Jonsson Comprehensive Cancer CenterWayne BrisbaneBlue Earth Diagnostics
Have you considered Estring clinical trials? We made a collection of clinical trials featuring Estring, we think they might fit your search criteria.Go to Trials
Image of Mayo Clinic in Florida in Jacksonville, United States.

Virtual Reality Assistant for Prostate Cancer

Any Age
Male
Jacksonville, FL
This clinical trial tests how well a point of prostate cancer diagnosis (PPCD) virtual reality assistant (ViRA) intervention works in supporting Black men with newly diagnosed prostate cancer. Cancer is the second leading cause of death for African American/Black men, with prostate cancer leading in estimated new cancer cases and second in estimated new cancer deaths. Over 40,000 African American/Black men are diagnosed with prostate cancer annually, with 1 in 6 lifetime probability of developing prostate cancer compared to 1 in 8 probability in White men. The PPCD ViRA provides psycho-oncology support, social determinants of health navigation and emotional support for ethnically diverse African American/Black men newly diagnosed with prostate cancer using artificial intelligence and augmented reality. Using PPCD ViRA may close the prostate cancer care gap for African American/Black men across the cancer continuum and provide emotional, educational, and resource needs of this population when they are visiting a doctor about their prostate health or prostate cancer.
Waitlist Available
Has No Placebo
Mayo Clinic in FloridaFolakemi T. Odedina, PhD
Have you considered Estring clinical trials? We made a collection of clinical trials featuring Estring, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security